MEDIA & PRESS UPDATES
October 17, 2019
ADAPTVAC RECEIVES INNOBOOSTER GRANT TO SUPPORT PRE-CLINICAL DEVELOPMENT OF A HER2 VIRAL CAPSID-LIKE PARTICLE VACCINE (AV001)
Hørsholm, Denmark, October 17, 2019 – AdaptVac announces that it has been awarded an InnoBooster grant by the Danish Innovation Foundation worth 0.8M DKK. The grant provides further support for the viral-capsid based vaccine platform technology by potentially demonstrating a safe and effective treatment for pet dogs diagnosed with DER2+ cancer, the canine protein homologous to human epidermal growth factor receptor 2 (HER2). This project forms part of our pre-clinical development in support of a human clinical development program.
19 February, 2019
ADAPTVAC RECEIVES DKK 2.6 MILLION GRANT FOR VACCINE PROJECT TO DRAMATICALLY REDUCE ANTIBIOTIC USE IN THE SWINE INDUSTRY
Hørsholm, Denmark, February 19, 2019 – AdaptVac announces its participation in a new vaccine development project aimed at preventing post-weaning diarrhea (PWD), a major cause of antibiotic use in the swine industry. The project has been awarded a Grand Solutions grant worth DKK 11 million by the Danish Innovation Foundation, of which DKK 5 million supports Virus-Like Particle (VLP) platform technology development with DKK 2.6 million earmarked for AdaptVac.
20 December, 2018
ADAPTVAC RECEIVES INDUSTRIAL POST-DOCTORAL GRANT TO SUPPORT AV001 PRE-CLINICAL DEVELOPMENT
Hørsholm, Denmark, December 20, 2018 – AdaptVac announces that it has been awarded an Industrial grant by the Danish Innovation Foundation worth 1.2M DKK. The grant supports a three-year Ind. Post-Doctoral project focused on demonstrating AV001 as a safe and effective treatment for pet dogs diagnosed with HER2+ cancer. This project forms part of AV001’s pre-clinical development in support of AdaptVac’s human clinical development program.
20 December, 2018
ADAPTVAC RECEIVES INDUSTRIAL PHD GRANT AND INITIATES NEW VACCINE DEVELOPMENT RESEARCH PROGRAM IN CARDIOVASCULAR DISEASE
Hørsholm, Denmark, December 20, 2018 – AdaptVac announces that it has been awarded an Industrial PhD grant by the Danish Innovation Foundation worth DKK 1 million. The grant will support a three-year virus-like particle vaccine Ind. PhD research program focused on PCSK-9, a billion-dollar monoclonal antibody validated cardiovascular disease target.
10 September, 2018
GRANTING OF ADAPTVAC’S HER2 CANCER VACCINE PATENT IN THE UNITED STATES
Hørsholm, Denmark, September 10, 2018 – AdaptVac announces allowance of its U.S. divisional patent application “Virus-like particle with efficient epitope display" by the USPTO. The divisional patent provides intellectual property protection for the U.S. market of AdaptVac’s novel vaccine targeting HER2-positive cancer (AV001). Furthermore, allowance of the divisional patent in the U.S. validates the patentability of AdaptVac’s virus-like particle technology platform patent portfolio.
28 November, 2017
PROOF OF CONCEPT IN ANIMALS FOR ADAPTVAC’S BREAST CANCER VACCINE PUBLISHED IN SCIENTIFIC JOURNAL
AdaptVac announces that the scientific article "Virus-like particle display of HER2 induces potent anti-cancer responses" is published in the peer reviewed journal ´OncoImmunology´, and will be available online on November 28, 2017. The paper presents proof of concept in animals (POCA) for AV-001, AdaptVac’s novel vaccine targeting HER2 positive breast cancer tumours. The vaccine is demonstrated to be effective both in prevention and therapy of mammary carcinomas in HER2 transgenic mice.
18 October 2017
ADAPTVAC REACHES PROOF OF CONCEPT IN ANIMALS FOR BREAKTHROUGH BREAST CANCER VACCINE TREATMENT
AdaptVac announces that it has reached proof of concept in advanced animal models (POCA) for AV-001, its novel vaccine treatment against breast cancer tumours. This is a significant milestone for the Company in the progress towards clinical development. The Company will now initiate discussions with large pharmaceutical companies regarding a license or collaboration agreement for the clinical development of the project.